Prosight Management, LP Biomarin Pharmaceutical Inc Transaction History

Prosight Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $1.82 Million - $2.84 Million	-22,900 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $4.98 Million - $6.76 Million	-69,837 Reduced 75.31%	22,900 $1.94 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $178,991 - $240,540	2,785 Added 3.1%	92,737 $7.84 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $2.61 Million - $3.3 Million	38,752 Added 75.69%	89,952 $6.06 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $496,884 - $580,677	-6,184 Reduced 10.78%	51,200 $4.39 Million
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $3.84 Million - $4.5 Million	-45,616 Reduced 44.29%	57,384 $5.1 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $526,680 - $697,092	6,572 Added 6.82%	103,000 $8.77 Million
Q3 2018 Nov 15, 2018	BUY	$93.92 - $105.72 $3.62 Million - $4.07 Million	38,528 Added 66.54%	96,428 $9.35 Million
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $418,055 - $544,665	-5,500 Reduced 8.68%	57,900 $5.45 Million
Q1 2018 May 14, 2018	BUY	$77.67 - $92.63 $4.92 Million - $5.87 Million	63,400 New	63,400 $5.14 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.